» Articles » PMID: 20077526

A Five-gene Signature As a Potential Predictor of Metastasis and Survival in Colorectal Cancer

Overview
Journal J Pathol
Specialty Pathology
Date 2010 Jan 16
PMID 20077526
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

To understand the molecular mechanisms of metastasis and prognosis of colorectal cancer (CRC), we isolated single cell-derived progenies (SCPs) from SW480 cells in vitro and compared their metastatic potential in an orthotopic CRC tumour model in vivo. Two groups of SCPs with the capability of high and low metastasis, respectively, were obtained. By analysing the gene expression profiles of high (SCP51), low (SCP58) metastatic SCPs, and their parental cell line (SW480/EGFP), we demonstrated that 143 genes were differentially expressed either between SCP51 and SCP58 or between SCP58 and SW480/EGFP. Gene-annotation enrichment analysis of DAVID revealed 80 genes in the top ten clusters of the analysis (gene enrichment score > 1). Of the 80-gene set, 32 genes are potentially involved in metastasis, as revealed by Geneclip. Five putative metastatic genes (LYN, SDCBP, MAP4K4, DKK1, and MID1) were selected for further validations. Immunohistochemical analysis in a cohort of 181 CRC clinical samples showed that the individual expression of LYN, MAP4K4, and MID1, as well as the five-gene signature, was closely correlated with lymph node metastasis in CRC patients. More importantly, the individual expression of LYN, MAP4K4, SDCBP, and MID1, as well as the five-gene signature, was significantly correlated with overall survival in CRC patients. Thus, our five-gene signature may be able to predict metastasis and survival of CRC in the clinic, and opens new perspectives on the biology of CRC.

Citing Articles

Transcriptome-Based Survival Analysis Identifies as a Prognostic Marker in Gastric Cancer with Microsatellite Instability.

Huamani Ortiz A, Campos Segura A, Magano Bocanegra K, Velasquez Sotomayor M, Barron Pastor H, Llimpe Mitma de Barron Y Cancers (Basel). 2025; 17(3).

PMID: 39941781 PMC: 11816344. DOI: 10.3390/cancers17030412.


MicroRNA-98 as a novel diagnostic marker and therapeutic target in cancer patients.

Akhlaghipour I, Moghbeli M Discov Oncol. 2024; 15(1):385.

PMID: 39210158 PMC: 11362465. DOI: 10.1007/s12672-024-01270-z.


Overcoming radioresistance of breast cancer cells with MAP4K4 inhibitors.

Kwon Y, Lee M, Kim N, Nam G, Nam K, Jang H Sci Rep. 2024; 14(1):7410.

PMID: 38548749 PMC: 10978830. DOI: 10.1038/s41598-024-57000-6.


MAP4K4 regulates forces at cell-cell and cell-matrix adhesions to promote collective cell migration.

Delsin L, Plutoni C, Clouvel A, Keil S, Marpeaux L, Elouassouli L Life Sci Alliance. 2023; 6(9).

PMID: 37369604 PMC: 10300198. DOI: 10.26508/lsa.202302196.


MAP4K4 and cancer: ready for the main stage?.

Gonzalez-Montero J, Rojas C, Burotto M Front Oncol. 2023; 13:1162835.

PMID: 37223681 PMC: 10200945. DOI: 10.3389/fonc.2023.1162835.